Science, medicine, and the future: Cirrhosis: New research provides a basis for rational and targeted treatments

British Medical Journal

Volumn 327, Issue 7407, 2003, Pages 143-147

  Iredale, John P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIOXIDANT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; GAMMA INTERFERON; GLIOTOXIN; INTERLEUKIN 10; METALLOPROTEINASE; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLATELET DERIVED GROWTH FACTOR; RELAXIN; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; INFLAMMATION; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; STELLATE CELL; BLOOD; CONVALESCENCE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BIOLOGICAL MARKERS; CYTOKINES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASES; RECOVERY OF FUNCTION; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0038455747     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Annual report of the chief medical officer 2001. Liver cirrhosis - starting to strike at younger ages. www.doh.gov.uk/cmo/annual report2001/livercirrhosis.htm (accessed 1 Jul 2003).
2. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002;50:585-8.
3. National Center for Chronic Disease Prevention and Health Promotion. US Obesity Trends 1985 to 2000. www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm (accessed 1 Jul 2003).
4. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993;328:1828-35.
5. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-50.
6. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985;82:8681-5.
7. Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 1990;86:1641-8.
8. Wang SC, Ohata M, Schrum L, Rippe RA, Tsukamoto H. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem 1998;273:302-8.
9. Thompson KC, Maltby J, Fallowfield J, McAulay M, Millward-Sadler GH, Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation. Hepatology 1998;28:1597-606.
10. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000;118:655-60.
11. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. Anti-tumour necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-25.
12. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;10:1286-92.
13. Border WA, Ruoslahti E. Transforming growth factor beta in disease: the dark side of tissue repair. J Clin Invest 1992;90:1-7.
14. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;360:361-4.
15. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999;96:12719-24.
16. Bataller R, Brenner D. Hepatic stellate cells as a target for the treatment of liver fibrosis. Seminars in Liver Disease 2001;21:437-51.
17. Benyon RC, Arthur MJP. Extracellular matrix degradation and the role of hepatic stellate cells. Seminars in Liver Disease 2001;21:373-84.
18. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJP. Expression of tissue inhibitor of metalloproteinases-1 and -2 is increased in fibrotic human liver. Gastroenterology 1996;110:821-31.
19. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inbibitors. J Clin Invest 1998;102:538-49.
20. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burkhardt E, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001;35:749-55.
21. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
22. Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001;121:685-98.
23. Imuro Y, Nishio T, Morimoto T, Nitta T, Stefanovic B, Choi SK, et al Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003;124:445-58.
24. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Seminars in Liver Disease 2002;21:337-49.
25. Rosenberg W, Burt A, Becka M, Voelker M, Arthur MJE Automated assays of serum markers of liver fibrosis predict histological hepatic fibrosis. Hepatology 2000;32:183A.
26. Friedman SL, Arthur MJP. Reversing hepatic fibrosis. Sci Med 2002;8:194-205.